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Introduction 
Drug resistance in Mycobacterium tuberculosis (TB) has become 
a severe global health threat. The fight against TB faces major chal-
lenges due to the appearance of Multi-Drug Resistant Tuberculosis 
(MDR-TB) and more recently, the virtually untreatable Extensively 
Drug Resistant Tuberculosis (XDR-TB). MDR-TB are strains that 
are resistant to both top first-line drugs, Isoniazid and Rifampin, 
while XDR-TB are MDR-TB strains that are also resistant to any 
fluoroquinolone and one or more of 3 injectable drugs. With this 
new resistance there emerges a need to find new drugs that are 
as effective yet bypass the problem of resistance. One method 
of research is to find new vulnerabilities of M. tuberculosis to 
use as new target sites of drugs. This method is highly expensive 
and requires intense and lengthy research just to implicate a new 
target site (Scheffler et al., 2013). An alternative is to develop new 
drugs that work on the same known targets as the first-line drugs 
but by different mechanisms thereby bypassing the resistance of 
TB to the drug.
Isoniazid (INH) is a powerful anti-TB drug that works by inhibiting 
the action of InhA, a crucial enzyme in the process of manufactur-
ing the cell wall. Instead of searching for new targets on TB, there 
is a goal to expand on this target and develop drugs that inhibit 
InhA by different mechanisms and thus show anti-tubercular activ-
ity against MDR-TB strains. 
The virulence of tuberculosis is due to its greatly complex cell 
envelope. Mycobacteria contain cell walls with unusually high lipid 
content due mainly to the presence of mycolic acids which are 
alpha-alkyl, beta-hydroxy fatty acids with atypically long alpha alkyl 
chains (up to C ). The existence of mycolic acids in the cell wall 
makes the cell impervious to common antibiotics (Niederweis et 
al., 2010). Mycolic acids were shown to be essential for the sur-
vival of tuberculosis thereby making them a great target for drug 
therapy. InhA (NADH-dependent-2-trans-enoyl-ACP-reductase)’s 
role in mycolic acid biosynthesis is catalyzing the final step in a 
cycle of elongation by reducing 2-trans-enoyl chains to their satu-
rated forms (Takayama et al., 2005).
Isoniazid (INH) has been used to treat tuberculosis since 1952. It 
is a prodrug that enters cells via passive diffusion where is it then 
converted from an inactive nontoxic form to its active toxic form. 
This conversion is mediated by KatG, a mycobacterial multi-func-
tional catalase-peroxidase that activates INH by peroxidation to 
form a variety of intracellular INH-derived radical species. The key 
intermediate in this reaction is the isonicotinoyl radical (Figure 1, 
compound 3) which then covalently binds to coenzyme NAD+ 
to generate an isonicotinoyl-NAD adduct (INH-NAD) (Timmins, 
Deretic, 2006). The addition of the isonicotinoyl radical to NAD+ 
creates a stereocenter in the INH-NAD adduct, and it is the acy-
clic 4S isomer that selectively binds to InhA as a slow tight-binding 
competitive inhibitor (K = 0.75 nM) (Rozwarski et al., 1998; Rawat 
et al., 2003). The binding of the INH-NAD adduct inhibits InhA 
from taking part in mycolic acid biosynthesis leading to impaired 
cell wall integrity and eventual cell death. 
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Despite its powerful anti-TB potential, the foremost problem with 
INH is the increasing resistance to the drug. In fact, INH resistance 
is the most common type of drug-resistant TB. The predominant 
mechanism of such resistance involves a single point mutation in 
the gene that codes for the KatG enzyme which results in an 
amino acid change from serine to asparagine at position 315 in the 
heme binding catalytic domain of KatG (Zhang, Yew, 2009). This 
S315T mutant is observed to contain a narrower heme access 
channel on KatG (4.7 Å compared to the wild type 6 Å) suggest-
ing that the loss of INH access to the oxidizing site of KatG might 
be the key to INH-resistance (Timmins, Deretic, 2006). While 
isolates with this mutation completely lose the ability to form 
the INH-NAD adducts, most retain good catalase activity and are 
therefore able to survive despite the mutation (Gumbo, 2011). 
Less commonly, resistance is also seen to occur by mutations in 
the promoter region of the InhA gene, leading to overexpression 
of InhA; or by mutations at the active site of InhA, resulting in 
lower InhA affinity to the INH-NAD adduct (Zhang, Yew, 2009). 
There are many methods of drug development. Older methods 
rely on trial and error testing of chemical substances on cells or 
whole organisms. This method is extremely lengthy and expensive 
as it requires the screening of hundreds of thousands of com-
pounds for activity. A newer method called rational drug design 
employs prior detailed knowledge of a vulnerable target and its 
three-dimensional structure to synthesize biologically active com-
pounds that specifically interact with the target. One manner of 
rational drug design is structure-based drug design, which employs 
the principle of SAR (Structure-Activity Relationship) that the-
orizes that similarly structured molecules have similar activities. 
Thus, if a compound is known to possess a desired activity, the 
essential functional groups and moieties responsible for this activ-
ity can be identified and a variety of new compounds containing 
those groups can be synthesized. The new compounds will then 
be tested for efficacy and functional similarity to the parent com-
pound. SAR commonly employs the use of molecular mechanics/
dynamics software to analyze and predict the conformations of 
known molecules and to subsequently model the conformational 
changes that occur in a bound target molecule. This information 
is then used to predict how similar synthesized compounds may 
interact with the target. Additionally, the 3D structure of a target 
molecule both alone and in complex with the synthesized com-
pounds is frequently obtained through X-ray crystallography and 
NMR spectroscopy to determine the underlying basis for the effi-
cacy (or lack thereof) of the newly synthesized compounds.
In the following literature review, a variety of SAR studies that 
attempted to find novel InhA inhibitors are summarized. The ma-
jority of the compounds discussed used a backbone of the biocide 
triclosan to create triclosan derivatives and substituted diphenyl 
ethers that exhibit InhA inhibition as well as efficacy against a 
variety of tuberculosis strains. Additionally, arylamide moieties 
have been confirmed as good InhA inhibitors although additional 
research is still needed to improve their anti-tubercular activity. 
Lastly, pyridomycin, a natural anti-Mycobacterial drug was recently 
rediscovered and shown to be effective against multiple strains of 
TB, as well as showing inhibition of InhA in a unique manner.
Methods
Literature searches were performed using the Touro College 
Online Library. In particular, the Health Sciences related databases 
(Medline, PubMed, Proquest Medical Library (Health and Medical 
Complete), and EBSCO Multisearch were employed. Additionally, 
Google Scholar and the Touro Quicksearch option proved to be 
very helpful in finding the necessary relevant articles. The follow-
ing keywords were searched: Mycobacteria, tuberculosis, InhA 
inhibitors, triclosan, triclosan derivatives, high affinity InhA inhibi-
tors, SAR, rational drug design, arylamides, pyridomycin. As a final 
point, only articles published in scholarly peer-reviewed journals 
after the year 2005 were included in the search. 
Results and Discussion
Triclosan derivatives and diphenyl ethers
The biocide triclosan (Figure 2), originally thought to have non-
specific antimicrobial activity, has been shown to target and un-
competitively inhibit enoyl reductases, the family of enzymes that 
includes InhA (Heath et al., 2001). Consistent with uncompetitive 
inhibition, triclosan binds to the enoyl reductases in the presence 
of NAD+. Triclosan is an excellent inhibitor of the E. coli enoyl 
reductase FabI with a picomolar inhibition constant (K = 7 pM) 
but is shown to be only a submicromolar inhibitor (K = 0.2 µM) 
of InhA (Ward et al., 1999). To understand the 30,000 fold differ-
ence in triclosan’s affinity for FabI versus InhA, crystal structures 
of FabI in complex with NAD+ and triclosan were compared to 
structures of InhA in complex with NAD+ and triclosan, so as to 
compare the ligand bindings and use the information to develop 
new inhibitors with high affinity for InhA (Sullivan et al., 2006).
The structures of triclosan bound to FabI and to InhA were gener-
ally very similar yet an important difference was seen with respect 
to the ordering of the amino acid loop that covers the substrate 
Figure 1
Structures of isoniazid (1), the isonicotinic hydrazyl radical (2) and the 
isonicotinoyl radical (3) Timmins, Deretic, 2006
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binding site of each enzyme. In the FabI:NAD:triclosan molecule, 
the substrate binding loop (residues 195-200) is ordered when 
triclosan is bound to it. In contrast, the substrate binding loop of 
InhA (residues 197-210) is disordered when triclosan binds to it. It 
has been suggested that ordering of the loop is indicative of slow, 
tight binding inhibition (Heath et al., 2001). When the substrate 
binding loop becomes structured, additional Van der Waals inter-
actions strengthen the binding. A key feature of slow-binding inhib-
itors is a conformational change in the enzyme upon drug binding. 
This is likely the slow step in the reaction, a hypothesis that is sup-
ported by the fact that triclosan has been identified as a slow, tight 
binding inhibitor of FabI but not InhA. Since slow-order kinetics 
has not been determined in the inhibition of InhA by triclosan, the 
loop is disordered in InhA (Sullivan et al., 2006). Ordering of the 
loop has been observed in the inhibition of InhA by the INH-NAD 
adduct, which has also been identified as a tight-binding inhibitor 
of InhA (Rawat et al., 2003), further supporting the hypothesis that 
connects slow, tight-binding inhibition to ordering of the active 
site loop.
Comparison of FabI and InhA crystal structures showed that InhA 
contains a larger substrate binding loop than FabI (14 residues vs. 
6 residues), making it harder to order the loop in InhA. Sullivan et 
al. hypothesized that longer substituents on the diphenyl ether A 
ring of triclosan might result in additional hydrophobic contacts 
between triclosan and the substrate binding pocket residues, and 
thereby increase the affinity for InhA. They removed the chlorine 
atoms from the B ring and substituted the chlorine atom on the A 
ring with alkyl groups of varying length (Figure 3).
As the length of the alkyl substituents increased from 2 carbons to 
8 carbons, the IC value (the concentration of inhibitor needed to 
inhibit 50% of the enzymes) decreased significantly from 2 µM to 
5 nM, indicating considerably higher affinity for InhA. In each case, 
the compounds were rapid, reversible uncompetitive inhibitors 
like the parent molecule triclosan. The most potent diphenyl ether, 
which was identified as 5-octyl-2-phenoxyphenol (8PP), displayed 
an IC of 5 nM (K =1.1 nM). The octyl chain in this molecule adopt-
ed a linear confirmation and burrowed into the pocket, forming 
numerous hydrophobic interactions with residues in the substrate 
binding loop which led to the observed significant increase in in-
hibitory activity. In addition to lower IC  values, the alkyl diphenyl 
ethers showed significantly lower MIC (minimum inhibitory con-
centration) values than triclosan (MIC 6.5µM vs. 43.1µM) against 
drug sensitive TB (H37Rv strain) as well as 5 INH resistant strains, 
thus demonstrating their potential for use against MDR-TB and 
validating the hypothesis that compounds that do not require ac-
tivation by KatG will be active against most INH resistant strains 
of TB. The results of this study revealed that the reason for the dif-
ferences in triclosan’s inhibition of FabI and InhA is that InhA has 
a large substrate binding loop that triclosan cannot fill as entirely 
as it can the smaller active site of FabI. Substituting alkyl chains 
on the triclosan molecule thus allowed for more hydrophobic in-
teractions deeper into the binding site and consequently higher 
affinity was demonstrated for InhA. Testing of the alkyl diphenyl 
ethers on H37Rv and 5 INH resistant strains confirmed that this 
higher affinity also led to greater anti-tubercular activity (Sullivan 
et al., 2006).
Treatment of TB is lengthy (6-24 months), so toxicity is a signif-
icant concern in the development of potential anti-tubercular 
drugs. The two most potent inhibitors identified by Sullivan et al., 
6PP and 8PP, were tested using a Vero cell line and shown to be 
five times less toxic than triclosan with a therapeutic index of 5-6 
compared to <1 for triclosan. Treatment with triclosan at 1xMIC 
for one day proved lethal to the cells. Furthermore, TB-infected 
macrophages treated with 2xMIC of 6PP and 8PP demonstrated 
high level growth inhibition, indicating an ability of these drugs 
to enter macrophages and remain effective against intracellular 
tuberculosis growth. Oral administration of 6PP and 8PP in mice 
also showed no adverse effects, substantiating a lower toxicity 
for these molecules. These studies demonstrated that alkyl substi-
tuted diphenyl ethers exhibited lower toxicity towards cells and 
TB-infected macrophages than did triclosan (Boyne et al., 2007).
While 6PP and 8PP showed high potency against InhA (nM inhibi-
tion constants) and improved efficacy against both drug-sensitive 
and drug-resistant strains, they were observed to have low bio-
availability with significantly high cLogP (partition coefficient) val-
ues (6PP= 6.47). The clogP value is important for predicting oral 
Figure 2:   
Molecular structure of triclosan Sullivan et al., 2006
Figure 3
Modified diphenyl ether inhibitors Sullivan et al., 2006
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absorption as it relates to a compound’s solubility and ability to 
permeate through cell membranes. Compounds that are too hy-
drophilic (low cLogP) are not able to pass through the hydropho-
bic membranes, while compounds that are too hydrophobic (high 
cLogP) tend to be insoluble and have trouble permeating through 
membranes because they can get stuck in the hydrophobic bilayer. 
In general, a cLogP greater than 5 predicts poor absorption or 
permeation (Lipinski et al., 2001).  
To lower the cLogP values, modifications were made to the B 
ring of the diphenyl ether backbone of 6PP. A series of analogs 
that incorporated different functional groups on the ring, designed 
to increase the polarity of the alkyl diphenyl ethers, were syn-
thesized. Two series were made: one series replaced the B ring 
with isosteric heterocycles that incorporated nitrogen atoms into 
the ring to increase polarity without added steric strain while the 
other series incorporated polar bulky substituents at different po-
sitions on the B ring. The results were primarily stereoselective. 
Overall, the addition of bulky substituents at either ortho, meta, 
or para positions of the B ring and the incorporation of most ni-
trogen heterocycles caused significantly higher MIC values and re-
duced inhibitory activity. However, the addition of nitro or amino 
substituents at ortho/para positions only slightly reduced inhib-
itory activity. While none of the newly synthesized compounds 
showed IC or MIC values lower than the parent compound 6PP, 
compounds 3c and 14a (Table 1) had inhibitory values similar to 
6PP but also had lower cLogP values (4.97 and 5.24 respectively). 
The results demonstrate that the addition of nitrogen containing 
compounds at certain positions on the B ring can lower the hy-
drophobicity of the compounds. Additional studies are needed to 
test whether the modifications result in increased bioavailability 
and improved in vivo antibacterial activity (amEnde et al., 2008). 
InhA has two hydrophobic cavities that are capable of being filled: 
the hydrophobic substrate binding pocket in which the substrate 
of InhA (2-trans-dodecenoyl-CoA) binds, and the NADH binding 
Table 1
Inhibition and solubility data for modified B ring heterocycles
Compound Structure IC5((nM) MIC (µg/ml) ClogP LogP
19 (6PP) 11± 1 2.1± 0.9 6.47 5.76
3c 160± 16 3.13 4.97 4.93
14a 62± 5 3.13 5.24
14b 1090± 90 100± 0
5.24
5.27
14c 55± 6 12.50 5.24 4.93
amEnde et al., 2008
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active site. The NADH active site sits underneath the substrate 
binding pocket and is lined primarily with hydrophobic residues. 
Most InhA inhibitors, including triclosan and its derivatives, inhibit 
InhA through binding to the substrate binding pocket. The compet-
itive inhibitor INH-NAD adduct, is one of the few inhibitors that 
binds directly to the NADH active site. Freundlich et al., (2009) 
observed the structure of InhA:NAD+:triclosan superimposed on 
InhA:INH:NAD and saw that the chlorine atom at position 5 of 
the triclosan A ring was only 2 Å from the binding pocket of the 
isonicotinoyl moiety of the INH-NAD adduct (Figure 4). They hy-
pothesized that triclosan derivatives can be synthesized that can 
extend into the hydrophobic isonicotinoyl binding pocket and in-
crease inhibition of InhA by occupying both the substrate binding 
pocket and the NADH binding site. This hypothesis was different 
than Sullivan et al. (2006) who created analogs to increase inter-
actions with the substrate binding loop, mimicking the structure 
of the substrate.
The analogs of Freundlich et al., were similar to those of Sullivan 
et al., but differed in that a variety of both hydrophobic and hy-
drophilic substituents were added to position 5 on the A ring. 
Additionally, contrary to the previous studies of Sullivan et al., it 
was suggested that the two chlorine atoms on the B ring do in fact 
participate in hydrophobic interactions with Phe97 and Met103 
residues and so they remained in the compounds. The results 
showed that the compounds with alkyl (hydrophobic) substitu-
ents were the more potent inhibitors. As seen with Sullivan et 
al., inhibition of InhA increased with increasing alkyl chain length. 
The highest inhibitory potencies for the alkyl chain additions were 
observed in the 4 carbon chain compounds (Table 2), namely 
compound 10 (Freundlich et al., 2009). 
Surprisingly, while most hydrophobic substituents were observed 
to show lower IC values, the addition of a phenyl group at the 5 
position (Compound 6) showed a much greater IC  (IC >10,000 
nM) than even triclosan (IC =1,100 nM). The same values were 
obtained for a pyridyl group at the 5 position. Modeling the inhibi-
tors in the active site showed that the aryl group was too far from 
the isonicotinoyl binding pocket by 2.5 Å and was also positioned 
too close to Phe149 which led to steric clashes. Therefore, to 
better fit the phenyl group into the hydrophobic pocket, a carbon 
linker chain consisting of 1-3 carbons was added to the 5 position 
(Compounds 24-26) between the phenyl group and the A ring. 
This resulted in significantly increased inhibitory potency of the 
phenyl substituted compounds (IC of 21-51 nM). Compound 25, 
with a 2 carbon linker chain showed the lowest IC of all the com-
pounds tested with a measured potency 50 times that of triclosan. 
Adding linkers to the pyridyl substituents (Compunds 17-19) also 
proved effective in producing powerful inhibitors (IC  of 29-75 
nM).
Through analysis of crystal structures, it became apparent that the 
goal of mimicking the isonicotinoyl moiety and reaching the ison-
icotinoyl binding site was not possible. The triclosan derivatives 
did reach the isonicotinoyl binding site but they did not occupy 
the same volume as the INH-NAD adduct. Instead, their actions 
mimicked the substrate analogs like Sullivan et al.’s compounds 
did. Attempts to increase the volume of the triclosan analogs in 
order to mimic the isonicotinoyl moiety would cause a rotation 
of Phe149, which in turn would displace Tyr158 and result in the 
loss of a crucial hydrogen bond, leading to the complete loss of 
inhibitor binding. Therefore, it was concluded that triclosan deriv-
atives can only attempt to place their substituents near the bind-
ing pocket and increase hydrophobic interactions in a way that 
mimics the substrate rather than the isonicotinoyl-NAD adduct 
(Freundlich et al., 2009).
Six of Freundlich et al.’s compounds (three alkyl and three aryl 
with IC < 110 nM) were tested for anti-tubercular activity. All of 
the compounds were more active than triclosan against H37Rv 
strain (wild type). Additionally, all showed high inhibition against 
five INH resistant strains demonstrating their potential for use in 
treatment against MDR-TB. These results revealed that while tri-
closan analogs cannot be used to mimic the INH-NAD adduct in 
the isonicotinoyl binding pocket they can act as substrate analogs. 
The aryl and pyridyl substituents with carbon chain linkers as well 
as many straight chain substituents showed considerably lower 
IC  values than triclosan, displaying higher affinity for InhA. They 
also showed greater anti-tubercular activity than triclosan when 
tested against both drug-sensitive and drug-resistant tuberculosis 
(Freundlich et al., 2009).
Figure 4: 
Cross-section of the InhA active site with superimposed structures of InhA in 
complex with the INH-NAD adduct (colored in gold) and triclosan (white). 
The A ring chlorine of triclosan (cyan) is observed to be very close to the 




Feundlich et al., 2009
In vitro activities of select triclosan derivatives against InhA
Compound R1 R2 InhA IC5(nM)
Triclosan Cl Cl
1100± 180
6 Ph Cl >10000
10 (CH2)3 CH3 Cl 55± 20
14 2-pyridyl CN >10000
15 3-pyridyl Cl >10000
16 4-pyridyl CN >10000
17 CH2 (2-pyridyl) Cl 29± 11
18 CH2 (3-pyridyl) Cl 42± 10
19 CH2 (4-pyridyl) CN 75± 16
24 CH2 Ph Cl 51± 6
25 (CH2)2 Ph Cl 21± 8
26 (CH2)3 Ph Cl 50± 14
73
Novel inhibitors of InhA
One problem with the triclosan derivatives and diphenyl ethers 
thus far is that they are shown to be rapid reversible inhibitors of 
InhA. An important and vital factor of in vivo drug activity is long 
residence times on the targets. Furthermore, structures of the 
previous compounds had indicated a disordered substrate binding 
loop. It had earlier been theorized that slow onset inhibition is 
coupled with ordering of an active site loop, which leads to the 
closure of the substrate binding pocket. Luckner et al., (2010) at-
tempted to create a slow onset triclosan-derived inhibitor of InhA 
using the hypothesis that compounds with the ability to order 
the loop will be slow tight-binding inhibitors of InhA. They used 
Sullivan et al.’s 6PP analog as a backbone and introduced a variety 
of groups onto the B ring in the hopes of promoting increased 
hydrophobic interactions between the inhibitor and the loop 
residues. 
One resulting compound, PT70 (Figure 5), contained a methyl 
group ortho to the diphenyl ether linkage and showed a substan-
tially higher affinity for InhA, with a K  of 22 pM, a value 430-fold 
lower than that of 6PP (K =9.4 nM). Additionally, PT70 displayed 
slow-onset inhibition which is essential for in vivo antibacterial 
activity. Crystal structures of InhA:NAD+:PT70 showed that PT70 
binds to InhA in almost the same way that triclosan and its de-
rivatives do. The main difference in the binding is that the methyl 
group on PT70 generates additional hydrophobic interactions 
with Ala198, Met199, Ile202 and Val203 residues on the substrate 
binding loop, leading to a defined loop structure (Figure 6). The 
Figure 6
Loop ordering is observed upon slow binding inhibition. A) InhA•NAD+•8PP complex in the binding of 8PP (Sullivan et al.’s most potent inhibitor) to InhA. NAD+ 
is displayed in cyan and the 8PP molecule is in black. The substrate-binding loop is disordered in the 8PP structure, and the loop ends are depicted in red. B) 
InhA•NAD+•PT70 complex. The PT70 compound is depicted in black. The substrate-binding loop (shown in red) is ordered in this structure and covers the binding 
pocket. Luckner et al., 2010
Figure 7
Scaffold of He et al.’s arylamides He et al., 2007
Figure 5
Addition of a methyl group on the ortho position of the B ring of 6PP led to 
PT70, a slow onset, tight binding diphenyl ether inhibitor. Luckner et al., 2010
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ordered binding loop covers the entrance to the binding pocket 
locking PT70 inside and increases the residence time on the tar-
get. Kinetic data show that PT70 has a residence time of 24 min-
utes on the target, a 14,000 fold increase over the residence time 
of its parent compound 6PP (0.1 sec). This study also confirmed 
the hypothesis that ordering of the active site loop is coupled to 
slow-onset inhibition. Further research is needed to test PT70 
on tuberculosis strains to confirm that the increase in affinity of 
PT70 for InhA does indeed correlate with enhanced anti-bacterial 
activity (Luckner et al., 2010). 
Triclosan has been recognized as a great molecular scaffold for 
InhA inhibition. The previous studies all employed the diphenyl 
ether backbone of triclosan. Modifications to both the A and B 
ring demonstrated increased affinity for InhA which was also 
coupled to greater anti-tubercular activity. The compounds show 
tremendous promise for rational drug design and SAR use in the 
treatment of TB. Significantly, it was confirmed that these com-
pounds do not require KatG activation affording them great 
potential against the most common strains of drug-resistant TB. 
Further research is still needed to test the compounds in vivo to 
confirm their anti-tubercular capacity.
Arylamides
Arylamides (Figure 7) have also been identified as a potential scaf-
fold of InhA inhibitors. Using High Throughput Screening (HTS), 
He et al., (2007) identified a variety of arylamides all of which 
contained either a piperazine or piperidine compound as the core 
structure. Compounds with the piperazine scaffold exhibited the 
best inhibitory activity among the initial compounds tested, with 
compound a4 being the most potent inhibitor (IC =3.07 µM) 
(Table 3). In order to enhance inhibition, He et al. crystallized 
Compound b3 (IC  = 5.16 µM), containing a piperidine with InhA 
and NADH and that structure was used as a reference for future 
compounds. The key hydrogen bond seen in all enoyl reductase 
inhibition reactions, involving the catalytic residue Tyr158 was ob-
served in the structure. The carbonyl oxygen of the arylamide was 
hydrogen bonded to both the 2’-hydroxyl moiety of the nicotin-
amide ribose and to the hydroxyl group of Tyr158. The unsubsti-
tuted B ring fit into the substrate binding pocket and interacted 
with many hydrophobic residues there. However, underneath the 
B ring, extra space was observed (Figure 8). He et al. hypothesized 
that addition of hydrophobic substituents to the B ring could form 
more interactions and lead to higher affinity (He et al., 2007).
The most potent inhibitors found by He et al. using High Throughput Screening
Compound X N R1 R2 IC 5((µM)
a4 N 0 4-CH3 3-Cl 3.07± 0.48
b3 C 1 4-CH3 H 5.16± 0.45
He et al., 2007
Table 3
Figure 8
a) Inhibitor b3 bound to the active site of InhA. As illustrated, extra space 
is observed in the area below the B ring of the inhibitor b) Details of the 
InhA-b3 interactions. Relevant residues of the binding pocket are shown. The 
amide oxygen hydrogen-bonds with the 2`-hydroxyl moiety of the nicotinamide 
ribose and the hydroxyl group of Tyr158 (blue arrows). He et al., 2007
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A variety of arylamides containing the piperazine scaffold were 
synthesized. 12 of the 60 compounds synthesized showed high 
InhA inhibitory activity. All 12 contained large polyaromatic moi-
eties on the B ring, substantiating the hypothesis that larger sub-
stituents on the B ring form more interactions and lead to higher 
affinity. Compound p2 (Table 4) of the newly synthesized mole-
cules showed the highest inhibitory activity (IC = 90 nM), a 34 fold 
decrease in IC  when compared to compound a4, the most potent 
of the HTS compounds (He et al., 2007).
Unfortunately, when the new compounds were tested against the 
H37Rv strain for anti-tubercular activity, most had MIC values 
>125 µM (He et al., 2007). This data suggests that the inhibitors 
do not possess optimal membrane permeability, likely due to their 
amphiphilicity, caused by the hydrophobicity of the B ring substitu-
ents and simultaneous hydrophilicity of the potentially protonated 
C ring piperazine. 
Figure 9
Compound p2, the most potent arylamide inhibitor synthesized by He et 
al. (yellow) with NADH (purple) in the InhA substrate binding site. The rigid 
residues around the binding site are displayed in green, while the flexible 
residues are displayed in orange. As discussed, the A ring of the arylamide is 
situated near the rigid residues, while the B ring is near the flexible residues. 
Punkvang et al., 2010
Table 4
He et al., 2007







Punkvang et al. (2010) attempted to identify the reasons behind 
the suboptimal anti-tubercular activity of the arylamides and to 
propose modifications to the compounds to increase both their 
affinity for InhA and anti-tubercular activity. Using molecular dy-
namics, a computer simulation that mathematically predicts the 
physical movements of atoms and molecules, they investigated the 
structural features and dynamic behavior of the InhA-inhibitor 
interactions providing detailed information about the molecule’s 
flexibility and conformation. RMSF (root mean square fluctuation) 
of residues around the substrate binding site of InhA was cal-
culated to reveal the mobile flexibility of the residues. Residues 
96-99, 155-165, and 192-200 (located around the binding pocket 
of the aryl A ring of the arylamide) were shown to be too rigid 
to bind the arylamide inhibitors (Figure 9). In contrast, most of 
the residues around the aryl B ring binding pocket (100-104, 149-
154, 201-223) indicated greater flexibility consistent with He et 
al.’s proposal that additional large substituents can be added to 
the B ring to increase the number of hydrophobic interactions 
(Punkvang et al., 2010).
Crystal structures and subsequent kinetic studies identify aryl-
amides as competitive inhibitors of the substrate binding site 
of InhA. Consequently, arylamides should mimic the binding of 
the substrate. Superimposition of arylamide inhibitors bound to 
InhA and a substrate analog (trans-2-hexadecenoyl-(N-acetyl-
cysteamine)-thioester) (Figure 10a) bound to InhA shows the 
conformational change that occurs in the enzyme when the aryl-
amide or the substrate bind. It was observed that the A ring of 
the arylamide binds to the hydrophilic part of the pocket where 
the hydrophilic acetylcysteamine moiety of the substrate binds. In 
contrast, the B ring lies in the same site as the fatty acyl chain of 
the substrate surrounded by flexible hydrophobic residues (Figure 
10b). The hydrophilic A ring is favored in the hydrophilic site and 
the hydrophobic B ring substituent is favored in the area with the 
hydrophobic residues (Punkvang et al., 2010).
Based on this data, Punkvang et al. proposed a series of modifica-
tions to the arylamides to mimic substrate binding and increase 
inhibitory activity. Introduction of small hydrophilic substituents 
such as an NH moiety or an acetyl oxygen on the A ring can be 
used to mimic the analogous part of the substrate and increase 
the hydrophilicity of the ring. Care must be taken, however, to 
ensure that the substituents are not too large and do not lead to 
steric interactions with the inflexible A ring residues and preclude 
proper binding as discussed. Additionally, binding affinity of aryl-
amides can be increased with the addition of bulky hydrophobic 
substituents to the B ring (Punkvang et al., 2010). 
These results explained the findings of He et al. and led to sug-
gested future modifications of arylamides that may increase their 
inhibitory potency. Molecular dynamic simulations showed that 
only the hydrophobic part of the substrate binding pocket is flex-
ible enough to bind arylamide inhibitors. Therefore, the addition 
Figure 10a
Structure of the substrate analog, trans-2-hexadecenoyl-(N-acetylcysteamine)-
thioester Punkvang et al., 2010
Figure 10b
Superimposition of x-ray structures of compound p3, an arylamide inhibitor 
synthesized by He et al. (pink) and fatty acid substrate (purple) in the InhA 
substrate binding site. As discussed, the A ring binds to the hydrophilic part of 
the binding site where the acetylcysteamine moiety of the substrate binds. The 
B ring is shown to bind to the hydrophobic part of the binding site where the 
fatty acid chain of the substrate binds. Punkvang et al., 2010
Figure 11 
Pyridomycin structure Hartkoorn et al., 2012
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of bulky hydrophobic substituents on the B ring can increase the 
binding affinity for the arylamides and also potentially increase 
membrane permeability. More research is needed to synthesize 
these proposed compounds and to measure their InhA inhibitory 
properties as well as their anti-tubercular properties and to see if 
membrane permeability indeed increased.  
Pyridomycin
Discovered in 1953, pyridomycin (Figure 11) is a natural antibiot-
ic produced by the bacteria Streptomyces pyridomyceticus and 
Dactylosporangium fulvum that exhibits specific activity against 
Mycobacteria (Maeda et al., 1953). Nevertheless, since it was only 
discovered a short time after the introduction of isoniazid as an 
exceedingly effective treatment for tuberculosis, pyridomycin was 
neglected and research into the drug ceased. Presently, with the 
rise of INH-resistant strains of TB, it is imperative to reexamine 
effective alternatives to INH. Despite earlier reports of pyrido-
mycin’s effectiveness against Mycobacteria as a genus, its efficacy 
against M. tuberculosis specifically had not yet been completely 
demonstrated. Additionally, pyridomycin’s target and mechanism 
of action had also not yet been elucidated. Hartkoorn et al. (2012) 
ascertained the drug’s target and specificity, and assessed its effi-
cacy against TB.
Pyridomycin was tested to confirm earlier reports about its spec-
ificity, efficacy, and low toxicity. The new research showed pyrido-
mycin to be a competent inhibitor of all species of Mycobacteria 
including tuberculosis (MIC= 0.62-1.25 µg/ml). It remained inef-
fective against other genera of both gram positive and gram neg-
ative classification (MIC > 100 µg/ml), confirming its specificity 
to a feature unique to Mycobacteria. It effectiveness against TB-
infected THP-1 derived macrophages was verified which indicat-
ed its ability to physically enter macrophages and inhibit growth. 
Toxicity testing demonstrated pyridomycin’s higher selectivity for 
tuberculosis than for human cells with a selectivity index of >100-
fold. (Hartkoorn et al., 2012) 
The identity of the target of pyridomycin was obtained by select-
ing for mutant pyridomycin-resistant strains (PYR7) on solid me-
dium containing pyridomycin at 10xMIC (3µg/ml). The genome of 
mutant PYR7 was referenced to H37Rv (wild type strain) and an 
a443g point mutation in InhA was isolated in PYR7 which resulted 
in replacement of the aspartic acid at position 148 by a glycine 
(D148G). Asp148 was previously identified in the binding pocket 
of InhA thus validating this as pyridomycins’s target. Subsequent 
experiments involving overexpression of InhA and the resulting 
increase in pyridomycin resistance further confirmed these find-
ings (Hartkoorn et al., 2012).
Since the primary goal of research into pyridomycin was to de-
termine its potential as an alternative to isoniazid, pyridomycin 
was tested against INH-resistant strains of TB. KatG mutants 
(the majority of the resistant strains), despite being highly resis-
tant to INH (MIC >10 µg/ml), showed no resistance to pyrido-
mycin. This demonstrated that pyridomycin does not depend on 
catalase-peroxidase bioactivation and therefore holds increased 
potential for use against the more common KatG INH-resistant 
strain (Hartkoorn et al., 2012). The results of this research con-
firmed previous reports of pyridomycin’s selectivity for and effica-
cy against tuberculosis including H37Rv and INH-resistant strains.
As discussed earlier, InhA contains two essential sites: the NADH 
binding site and the lipid substrate binding pocket. Crystal 
structures and kinetic experimentation show that pyridomycin 
is a direct competitive inhibitor of NADH binding in InhA and 
occupies the NADH binding site. Pyridomycin forms several in-
teractions with residues in the NADH binding site including the 
crucial hydrogen bond between the side chain of Tyr158 and the 
C7 carbonyl oxygen of pyridomycin. Loss of this hydrogen bond 
and consequent lack of the crucial enoyl reductase-inhibitor inter-
action in D148G mutants (pyridomycin-resistant InhA) resulted 
in markedly decreased affinity for pyridomycin. Crystal structures 
show that, as a result of its unusually large size, pyridomycin not 
only occupies the NADH binding site, but its upper hemisphere 
also extends into the substrate binding pocket forming a hydro-
phobic interaction with Phe149. While previously identified InhA 
inhibitors exclusively inhibited only one of the sites, pyridomycin 
is the first published compound to bridge the gap between both 
sites and simultaneously inhibit the lipid substrate binding pocket 
as well as the NADH binding site (Figure 12) (Hartkoorn et al., 
2014).
Figure 12
Binding comparison of various InhA inhibitors. The blue area represents the lipid 
substrate binding pocket, while the red area represents the NADH binding site. 
a) The lipid substrate is bound to the substrate binding site. b) Triclosan 
derivatives have all been shown to bind solely to the substrate binding site. c) 
The INH-NAD adduct binds solely to the NADH binding site. d) Pyridomycin 
binds to the NADH binding site and, because of its large size, extends into the 
lipid substrate binding site as well. Hartkoorn et al., 2014
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Pyridomycin is a naturally produced antibiotic and efforts to syn-
thesize it have been hampered by the inability to form the double 
bond of the enol ester moiety between C1 and C2. The com-
pound was instead synthesized with a saturation in that position 
(and a replacement of the sec-butyl group with a symmetrical iso-
propyl group) to identify if the double bond was indeed necessary 
for anti-tubercular activity. Saturation generated a new stereo-
center, producing two stereoisomers: the R isomer (OH141) and 
the S isomer (OH139) (Figure 13). Both compounds, as well as 
natural pyridomycin were then tested for anti-tubercular activity. 
Pyridomycin was the most effective against TB (MIC = 0.39 µg/ml). 
OH139 had a MIC value 32-fold higher than pyridomycin while 
OH141 measured only 4-fold higher, indicating that the enol ester 
moiety is not actually a critical requirement for anti-TB activity 
(Horlacher et al., 2013).
X-ray crystallography and in silico modeling highlight the reasoning 
behind the difference in efficacy between the two stereoisomers. 
Superposition of InhA:pyr on InhA:OH141 show pyridomycin and 
OH141 occupying the same position in the active site. The isopropyl 
group of OH141 was found in the equatorial position avoiding any 
steric clashes with residues in the active site. OH139 however, was 
shown with its isopropyl group in a steric interaction with the side 
chain of Met199 in the substrate binding loop, indicating why OH139 
has a lower affinity for InhA than does OH141 (Horlacher et al., 
2013). The slight decrease in the activity of OH141 compared to pyr-
idomycin could be due to the lower hydrophobicity of the isopropyl 
group compared to the 2-butan-2-ylidene substituent. The results of 
this research demonstrate that pyridomycin can be synthesized with 
a saturation in the C1-C2 bond without significantly impacting its 
anti-tubercular activity. This establishes the potential for future SAR 
work in the development of pyridomycin-derived drug candidates 
for TB treatment. Current research is now focused on using OH141 
as a scaffold for synthesis of new pyridomycin variants.
Conclusion
In this review, SAR has been shown to be an effective means to 
structurally design and modify drugs to increase their InhA in-
hibition abilities. The underlying assumption of the research was 
that compounds that do not require KatG activation would be ef-
fective against most INH-resistant strains. This hypothesis proved 
correct in the case of triclosan and pyridomycin derivatives. 
Additional modifications to arylamides are needed to optimize 
their activity. Through analysis of crystal structures, along with 
computer-assisted molecular dynamics and modeling, a variety 
of high affinity compounds were synthesized. Current efforts are 




MDR-TB Multi Drug Resistant Tuberculosis
XDR-TB Extensively Drug Resistant Tuberculosis
INH  Isoniazid 
SAR  Structure Activity Relationship
IC50  Half maximal inhibitory concentration (the con-
centration of inhibitor at which half of the enzymes are inhibited)
K i    Inhibitory constant
MIC  Minimum Inhibitory Concentration
H37Rv  Wild type strain of TB 
cLogP  Calculated partition coefficient
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